Cingulate Inc. 10-Q Summary: Quarter Ended September 30, 2024
Business Context and Reporting Period
Cingulate Inc. (CING) is a biopharmaceutical company developing once-daily, multi-dose tablet therapies for ADHD and anxiety using its Precision Timed Release (PTR) platform. The company is a pre-revenue entity focused on advancing its lead candidate, CTx-1301 (dexmethylphenidate), toward a targeted New Drug Application (NDA) submission in mid-2025. This report covers the quarterly period ended September 30, 2024. The company is classified as a non-accelerated filer, a smaller reporting company, and an emerging growth company.
Key Financial Metrics
| Metric | Q3 2024 | Q3 2023 | 9 Months 2024 | 9 Months 2023 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Loss | $(3.23) million | $(5.98) million | $(9.41) million | $(16.60) million |
| Operating Loss | $(3.28) million | $(5.75) million | $(9.44) million | $(15.96) million |
| Cash and Equivalents (End of Period) | $10.04 million | $1.99 million | $10.04 million | $1.99 million |
| Accumulated Deficit | $(102.36) million | $(86.01) million | $(102.36) million | $(86.01) million |
| Stockholders' Equity | $12.04 million | $(0.10) million | $12.04 million | $(0.10) million |
Debt and Liquidity: As of September 30, 2024, the company had no outstanding notes payable, having converted all related-party debt to equity in early 2024. Total current liabilities were $1.54 million, primarily accounts payable and accrued expenses. The company reported a net increase in cash of approximately $10.0 million for the nine months ended September 30, 2024, driven by financing activities.
Material Changes vs. Prior Period
- Capital Raise: The company significantly improved its liquidity position through multiple equity issuances in 2024, including a public offering in February, a warrant inducement in June, and substantial sales under its At-The-Market (ATM) and Lincoln Park Purchase Agreements. Cash balances increased from $52,000 at year-end 2023 to $10.04 million at September 30, 2024.
- Expense Reduction: Net loss decreased by 36.6% in Q3 2024 compared to Q3 2023. Research and Development (R&D) expenses dropped 63.6% to $1.43 million, primarily due to the closure of enrollment in two Phase 3 pediatric studies for CTx-1301 and reduced clinical activity. General and Administrative (G&A) expenses remained relatively flat, increasing slightly by 1.5%.
- Reverse Stock Split: On August 9, 2024, the company completed a one-for-twelve reverse stock split to maintain compliance with Nasdaq listing requirements.
- Debt Elimination: The company eliminated its $3.0 million related-party note payable by converting it to pre-funded warrants in January 2024, removing interest expense from the income statement.
Guidance, Outlook, and Risks
Outlook and Guidance: Management targets an NDA submission for CTx-1301 in mid-2025. The company believes its current cash position of $10.0 million will satisfy capital needs into the third quarter of 2025 under its current business plan. However, additional funding will be required to advance other programs (CTx-1302, CTx-2103) and for commercialization efforts.
Management Commentary: The company is progressing with data consolidation for CTx-1301 and initiated a food effect study in September 2024. A European patent for CTx-1301 was issued in August 2024. The company is actively seeking strategic partnerships for the commercialization of CTx-1301.
Risks and Contingencies:
- Going Concern: The filing includes a substantial doubt disclosure regarding the company's ability to continue as a going concern within one year without additional funding, though financial statements are prepared on a going concern basis.
- Nasdaq Compliance: The company is under a one-year discretionary panel monitor (until May 2025) following previous non-compliance with Minimum Stockholders' Equity and Minimum Bid Price rules. Failure to maintain compliance could result in delisting.
- Capital Needs: There is no assurance that additional capital will be available on acceptable terms or at all. Failure to raise capital could force the company to delay or discontinue development.
Investor Verification Checklist
- Cash Runway: Verify the accuracy of the $10.0 million cash balance and the projected burn rate to confirm the "third quarter 2025" liquidity runway.
- Nasdaq Status: Monitor the company's stock price to ensure it remains above the $1.00 minimum bid price to avoid delisting risks under the panel monitor.
- CTx-1301 Timeline: Track the completion of the food effect study and the subsequent NDA submission timeline for mid-2025.
- Dilution Impact: Review the impact of recent equity issuances (ATM, Lincoln Park, Warrant Inducement) on share count and per-share value, noting the recent reverse split.
- Contractual Obligations: Assess the $1.8 million in estimated costs for data consolidation and the $1.5 million for the fasted food effect study against current cash reserves.